Market Research Reports and Industry Reports

Biosimilars Real World Evidence: Proving the point

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS



Biosimilars Real World Evidence: Proving the point

Biosimilar manufacturers face an uphill struggle to fully mobilise their product portfolio. Against a background of aggressive defence strategies by originator companies, often sceptical prescribers must be brought on board, the anxieties of patients reduced, and payer demands for lower prices addressed. Real World Data (RWD) and Real World Evidence (RWE) play a key role in building stakeholder confidence and establishing market presence.

In Biosimilars Real World Evidence: Proving the point, FirstWord analyses the strategies that lead to meaningful and trusted RWD and the critical role it plays for biosimilars in educating payers, physicians and patients on safety, efficacy and cost effectiveness.





Discover on this page

The executive summary below, taken directly from the report, presents key findings from the research
The rigorous research objectives and methodologies employed to produce the report
Detailed report contents
Why this report is important to you

Executive Summary

Understanding how drugs work in the real world marks a significant value proposition for stakeholders, including patients, prescribers and payers, largely because patients have characteristics and treatment experiences that can differ significantly from those observed in the hyper-controlled environment of a clinical trial.
The interest level for real-world data (RWD) in the pharmaceutical industry is high across the board, but has perhaps reached fever pitch for biosimilars, mainly because their abbreviated regulatory pathway can foster distrust about the safety and efficacy of these lower-cost therapies compared to their more rigorously reviewed reference products. However, collecting and analysing these data presents unique challenges for biosimilar manufacturers.
This report analyses the current RWD needs of various stakeholders and how biosimilar developers can put the right pieces together to form a comprehensive body of evidence that demonstrates the value of their products. Throughout this report, answers to the following questions are provided and discussed:

What types of RWD are most requested?
Biosimilars are promoted as a cheaper alternative to costly biologicals, but taking this tack has led some experts to believe that cheaper is synonymous with not equivalent to the more costly originator therapies. Therefore, many stakeholders still very much crave additional data about the safety and efficacy of biosimilars, particularly in instances where indication extrapolation has been used to grant approval.

When and under what conditions should RWD be provided?
Currently, RWD are provided as part of a post-market approval agreement in the European Union (EU) or requested by payers in the US following market launch. However, the experts argue that it would be far more useful if these types of studies were performed in tandem with traditional clinical trials. This holds particularly true for any biosimilar approved via indication extrapolation, as often RWD represent the first data on the therapys use in a particular patient population, and thus would go a long way to assuage any prescriber and patient trepidation regarding the use of an untested treatment.

How influential are RWD for biosimilars?
The reach of RWD and real-world evidence (RWE) is somewhat stifled by the general lack of knowledge about biosimilars and what they entail. However, physicians still reference the data to help prove the sameness of the therapies, payers are leveraging the data to help inform where in the treatment algorithm the biosimilar should be positioned, and the manufacturers themselves are using the information to better connect with patients and patient advocacy groups.

How are biosimilar manufacturers creating RWD?



What are the challenges to providing RWD?
Current challenges to generating RWD include a lack of experience particularly in the US as well as the fact that not enough time has passed for long-term RWD to be collected. These challenges are certainly unique to biosimilars due to the areas relative lack of maturity, but this is expected to change as familiarity with the products increases.
How can RWD for biosimilars be enhanced and continually improved?

To improve the quality and applicability of RWD, the experts suggest that biosimilar manufacturers consider working more collaboratively with other stakeholders particularly regulatory agencies to help collect and disseminate information.

What is the future for RWD in biosimilars?
Provided some of the significant hurdles associated with generating RWD in this specialty are addressed, the experts suggest that these data could eventually become a cornerstone of regulatory applications and generally play a greater role in supporting the decision-making processes of all stakeholders.

Doctors Guide Publishing Limited. This executive summary is provided for commercial evaluation purposes only. It can be shared with colleagues for this purpose but cannot be reproduced, extracted or published without the express permission of the publisher.

Research Methodology and Objectives

Payers, health technology assessment agencies and other stakeholders are increasingly interested in knowing whether a medicine works in the real world, and not just in the trial setting. Real-world data (RWD) and real-world evidence (RWE) are key to answering their questions about the value of medicines in the real world.

The research methodology for this report included primary research through in-depth interviews with experts working within, and responsible for, RWD and RWE in pharmaceutical companies. These key insights are supported and contextualised by extensive desk research.

Key questions explored in this report include

What are RWD and RWE?
What is enabling RWD and what are the barriers for RWD?
Why is there so much interest in RWD and RWE?
How important are RWD and RWE for market access?
How are RWD and RWE being used in market access?
Which companies are leading on RWD and RWE?
What can companies benchmark themselves against for RWD and RWE in market access?
What is the future for RWD and RWE?

Table of Contents
Executive summary
Research methodology and objectives
Experts interviewed for this report
Real-world data: a brief history

Table of Contents
Executive summary
Research methodology and objectives
Experts interviewed for this report
Real-world data: a brief history

Diversity in real-world data
The perceived benefits of RWD
Real-world data for biosimilars
Challenges for real-world data
The biosimilar market and the need for RWD
Key insights
Barriers to greater biosimilar uptake
Role of RWD in biosimilar uptake
RWD can represent first evidence of biosimilar efficacy and safety
Indications where RWD most influential
RWD information needs by stakeholder type
The mechanics of providing RWD
Key insights
Stakeholder requests for RWD
Stakeholders argue for earlier access to RWD
Multiple RWD sources of use, but each has limitations
Future effectiveness of switching studies as RWD source
Implications of RWD on various stakeholders
Stakeholders most influenced by RWD
Barriers to greater RWD utility
Strategies for implementing RWD
Key insights
Manufacturer goals for RWD research
How manufacturers procure RWD and RWE
Stakeholder perceptions on types of RWD
Data needs in the US and EU
Questions to be considered before proceeding with RWD studies
RWD trial design types for biosimilars
The future of RWD in biosimilars
Key insights
Future opportunities for biosimilar RWD
RWD types most valuable for biosimilars
Ongoing challenges in generating RWD
Future strategies to improve quality and applicability of RWD
RWDs future role in regulatory decisions
SWOT analysis for RWD in biosimilars
Tables of Figures
Figure 1: Sources of real-world data
Figure 2: How to determine the credibility of observational studies
Figure 3: SWOT analysis for RWD in biosimilars
Tables of Figures
Table 1: Data needs in the US vs EU
Table 2: Post-approval studies for recently approved biosimilars

Why this report is important to you

Interest in real-world data has reached fever pitch in recent years, particularly for biosimilars, where data to illustrate safety and efficacy outside of the controlled confines of the clinical trial environment is frequently requested by stakeholders. This report analyses the current RWD needs of various stakeholders and how biosimilar developers can put the right pieces together to form a comprehensive and persuasive body of evidence that demonstrates the value of their therapies.

This report will enable you to

Understand what RWD and RWE are and who is driving demand
Identify the barriers developers must overcome in collecting RWD that is meaningful and trusted by stakeholders
Learn why there is so much stakeholder interest in RWD and RWE and how it must be nuanced to meet different needs
Appreciate how demand for RWD/RWE differs in the US and EU
Assess the critical importance of RWD and RWE for biosimilar market access
Evaluate the RWD and RWE strategies that are being successfully used today
Anticipate the future biosimilar RWD and RWE climate

Pharma RWD/RWE Expert Contributors

The report is informed by the practical knowledge and insights of 13 RWD/RWE experts, and includes contributions from people who work for leading companies such as Pfizer, Amgen and Celltrion.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your companys success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


1. Executive summary
2. Research objectives and methodology
3. Experts interviewed
4. Real-world data: a brief history
4.1 Diversity in real-world data
4.2 The perceived benefits of RWD
4.3 Real-world data for biosimilars
4.4 Challenges for real-world data
5. The biosimilar market and the need for RWD
5.1 Key insights
5.2 Barriers to greater biosimilar uptake
5.3 Role of RWD in biosimilar uptake
5.4 RWD can represent first evidence of biosimilar efficacy and safety
5.5 Indications where RWD most influential
5.6 RWD information needs by stakeholder type
6. The mechanics of providing RWD
6.1 Key insights
6.2 Stakeholder requests for RWD
6.3 Stakeholders argue for earlier access to RWD
6.4 Multiple RWD sources of use, but each has limitations
6.5 Future effectiveness of switching studies as RWD source
6.6 Implications of RWD on various stakeholders
6.7 Stakeholders most influenced by RWD
6.8 Barriers to greater RWD utility
7. Strategies for implementing RWD
7.1 Key insights
7.2 Manufacturer goals for RWD research
7.3 How manufacturers procure RWD and RWE
7.4 Stakeholder perceptions on types of RWD
7.5 Data needs in the US and EU
7.6 Questions to be considered before proceeding with RWD studies
7.7 RWD trial design types for biosimilars
8. The future of RWD in biosimilars
8.1 Key insights
8.2 Future opportunities for biosimilar RWD
8.3 RWD types most valuable for biosimilars
8.4 Ongoing challenges in generating RWD
8.5 Future strategies to improve quality and applicability of RWD
8.6 RWDs future role in regulatory decisions
8.7 SWOT analysis for RWD in biosimilars

The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events

The Future of Biosimilars in the USACan pharma resolve the litigation frenzy hampering biosimilars market entry in the US Is too much focus on legal wrangling stifling healthy competition and

USD 2245View Report

Biosimilars Real World Evidence: Proving the point

Biosimilars Real World Evidence: Proving the point Biosimilar manufacturers face an uphill struggle to fully mobilise their product portfolio. Against a background of aggressive defence strategies by originator companies, often

USD 2245View Report

Real World Data -- Meeting payer needs

How to adjust your Real World Data provision to address the real needs of payersDrug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are

USD 2245View Report

Real World Data Capabilities: Benchmarking pharma companies

DescriptionIntroductionnIs Real World Data giving your market access the power charge it needs Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front

USD 695View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2245
  • Enterprise Wide Licence    USD 15395
$ 2245

Reports Details

Published Date : Jul 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
pendik escort tuzla escort antalya escort bayan kartal escort
instagram takipci hilesi
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop